Table 1 Demographic and clinical characteristics of patients with enterococcal BSIs
Total (n = 226) | E. faecium (n = 167) | E. faecalis (n = 46) | p-value | |
|---|---|---|---|---|
Demographics | ||||
Age | 65 (54–75) | 65 (55–75) | 66 (52–79) | 0.450 |
Male gender | 142 (63, 56–69) | 104 (62, 55–70) | 31 (67, 53–81) | 0.524 |
BMI, median | 23 (20–26) | 22 (20–25) | 24 (23–26) | 0.006 |
Comorbidities | ||||
Malignancy | 130 (58, 51–64) | 95 (57, 49–64) | 26 (57, 42–71) | 0.965 |
Cardiovascular disease | 113 (50, 43–57) | 78 (47, 39–54) | 28 (61, 46–76) | 0.089 |
Pneumonia | 74 (33, 27–39) | 60 (36, 29–43) | 14 (30, 17–44) | 0.488 |
Diabetes mellitus | 68 (30, 24–36) | 45 (27, 20–34) | 18 (39, 24–54) | 0.109 |
Impaired liver function | 52 (23, 17–29) | 41 (25, 18–31) | 7 (15, 4–26) | 0.180 |
Cerebrovascular disease | 41 (18, 13–23) | 34 (20, 14–27) | 5 (11, 2–20) | 0.141 |
Impaired renal function | 30 (13, 9–18) | 22 (13, 8–18) | 7 (15, 4–26) | 0.720 |
Hemiplegia | 27 (12, 8–16) | 24 (14, 9–20) | 2 (4, 0–10) | 0.066 |
Neutropenia | 14 (6, 3–9) | 12 (7, 3–11) | 2 (4, 0–10) | 0.492 |
CCI, median | 3 (2–6) | 3 (2–6) | 2 (1–4) | 0.014 |
APACHE II score, median | 8 (5–11) | 8 (5–11) | 7 (5–12) | 0.501 |
Hospitalization ward | ||||
Medical | 88 (39, 33–45) | 68 (41, 33–48) | 14 (30, 17–44) | 0.204 |
Surgical | 84 (37, 31–44) | 56 (34, 26–41) | 22 (48, 33–63) | 0.075 |
ICU | 54 (24, 18–29) | 43 (26, 19–32) | 10 (22, 9–34) | 0.578 |
Length of hospital stay, median days | ||||
Prior hospital stay | 15 (9–27) | 16 (10–28) | 14 (7–25) | 0.065 |
Hospital stay after onset of BSIs | 18 (8–29) | 18 (8–29) | 18 (8–33) | 0.906 |
Previous treatment | ||||
Antibiotic exposure | 210 (93, 90–96) | 160 (96, 93–99) | 41 (89, 80–98) | 0.082 |
Total parenteral nutrition | 84 (37, 31–44) | 60 (36, 29–43) | 22 (48, 33–63) | 0.142 |
Mechanical ventilation | 87 (38, 32–45) | 63 (38, 30–45) | 20 (43, 29–58) | 0.479 |
Surgery | 74 (33, 27–39) | 49 (29, 22–36) | 20 (43, 29–58) | 0.070 |
Chemotherapeutic agent | 29 (13, 8–17) | 24 (14, 9–20) | 3 (7, 0–14) | 0.153 |
Immunosuppressive agent | 18 (8, 4–12) | 16 (10, 5–14) | 2 (4, 2–10) | 0.259 |
Renal replacement therapy | 15 (7, 3–10) | 12 (7, 3–11) | 3 (7, 0–14) | 0.876 |
Invasive devices | ||||
Central intravenous catheter | 102 (45, 39–52) | 82 (49, 41–57) | 16 (35, 20–49) | 0.084 |
Indwelling urinary catheter | 104 (46, 39–53) | 75 (45, 37–53) | 25 (54, 39–69) | 0.256 |
Endotracheal intubation | 86 (38, 32–44) | 60 (36, 29–43) | 22 (48, 33–63) | 0.142 |
Peripheral intravenous catheter | 69 (31, 24–37) | 50 (30, 23–37) | 14 (30, 17–44) | 0.948 |
Tracheostomy tube | 20 (9, 5–13) | 15 (9, 5–13) | 4 (9, 0–17) | 0.952 |